Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS

Fabiola Traina, MD, PhD, Anna M Jankowska, PhD, Valeria Visconte, PhD, Yuka Sugimoto, MD, PhD, Hadrian Szpurka, PhD, Hideki Makishima, MD, PhD, Andres Jerez, MD, Christine L. O'Keefe, PhD, Mikkael A. Sekeres, MD, MS, Anjali S. Advani, MD, Yogen Saunthararajah, MD, Matt Kalaycio, MD, Edward A. Copelan, MD, Sara T. Olalla Saad, MD, PhD, Jaroslaw P Maciejewski, MD, PhD, Ramon V. Tiu, MD

Blood (2011) 118 (21): 461.

https://doi.org/10.1182/blood.V118.21.461.461

Published: 2011

Journal Articles

Association of SF3B1 with Ring Sideroblasts in patients, In Vivo, and In Vitro models of Spliceosomal Dysfunction

Blood (2011) 118 (21): 457.

https://doi.org/10.1182/blood.V118.21.457.457

Published: 2011

Journal Articles

Mechanisms of Defective Hydroxylation of 5-Methylcytosine in MDS Include Pathways Other Than TET2 and IDH1/2

Anna M Jankowska, PhD, Yun Huang, PhD, Myunggon Ko, PhD, Utz J Pape, PhD, Hideki Makishima, MD, PhD, Hadrian Szpurka, PhD, Fabiola Traina, MD, PhD, Valeria Visconte, PhD, Ramon V Tiu, MD, Mikkael A Sekeres, MD, Anjana Rao, PhD, Jaroslaw P Maciejewski, MD, PhD

Blood (2011) 118 (21): 462.

https://doi.org/10.1182/blood.V118.21.462.462

Published: 2011

Journal Articles

Consequences of UTX Dysfunction in Myelodysplastic Syndrome

Anna M Jankowska, PhD, Hadrian Szpurka, PhD, Venugopalan Cheriyath, PhD, Kwok Peng Ng, PhD, Zhenbo Hu, MD, Michael A McDevitt, MD, Yogen Saunthararajah, MD, Jaroslaw P. Maciejewski, MD, PhD

Blood (2011) 118 (21): 2427.

https://doi.org/10.1182/blood.V118.21.2427.2427

Published: 2011

Journal Articles

Spliceosome GENE MUTATIONS ARE Also PRESENT In the Diverse Mutational Spectrum of CHRONIC Myelomonocytic LEUKEMIA

Hideki Makishima, MD, PhD, Anna M Jankowska, PhD, Valeria Visconte, PhD, Ramon V. Tiu, MD, Kathryn M Guinta, Hadrian Szpurka, PhD, Yuka Sugimoto, MD, PhD, Christine L. O'Keefe, PhD, Alan F. List, MD, Mikkael A Sekeres, MD, Michael A McDevitt, MD, PhD, Jaroslaw P. Maciejewski, MD, PhD

Blood (2011) 118 (21): 1402.

https://doi.org/10.1182/blood.V118.21.1402.1402

Published: 2011

Journal Articles

Next Generation Exome Sequencing for Identification of the Gene Mutations Associated with Loss of Heterozygozity on Chromosome 7 In Myeloid Malignancies

Yuka Sugimoto, MD, PhD, Hideki Makishima, MD, PhD, Hadrian Szpurka, PhD, MSC, Anna Jankowska, MSC, Kathryn Guinta, Ramon V. Tiu, MD, Christine L. O'Keefe, PhD, Alison R Moliterno, MD, Michael A McDevitt, MD, PhD, Hideki Muramatsu, MD., PhD, Seiji Kojima, MD, PhD, Mehdi Keddache, MSC, Jaroslaw Maciejewski

Blood (2010) 116 (21): 297.

https://doi.org/10.1182/blood.V116.21.297.297

Published: 2010

Journal Articles

Identification of Oncogenic EZH2 Mutations In Myelodysplastic Syndromes and Related Myeloid Malignancies

Hideki Makishima, MD, PhD, Ania Jankowska, MSC, Ramon V. Tiu, MD, Hadrian Szpurka, PhD, MSC, Yuka Sugimoto, MD, PhD, Quteba Ebrahem, MD, Zhenbo Hu, MD, Reda Mahfouz, MD, Yogen Saunthararajah, MD, Kathryn Guinta, Mehdi Keddache, MSC, Christine L. O'Keefe, PhD, Mikkael A. Sekeres, MD, MS, Alan F. List, Michael A McDevitt, MD, PhD, Jaroslaw P Maciejewski, MD, PhD, FACP

Blood (2010) 116 (21): 607.

https://doi.org/10.1182/blood.V116.21.607.607

Published: 2010

Journal Articles

Mutational Spectrum In Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such as UTX and EZH2

Anna Jankowska, MSc, Hideki Makishima, MD, PhD, Ramon V. Tiu, MD, Hadrian Szpurka, PhD, MSc, Yun Huang, Yuka Sugimoto, MD, PhD, Courtney Prince, BS, Christine L. O'Keefe, PhD, Eric Hsi, MD, Alan F. List, Mikkael A. Sekeres, MD, MS, Anjana Rao, PhD, Michael A McDevitt, MD, PhD, Jaroslaw P Maciejewski, MD, PhD, FACP

Blood (2010) 116 (21): 611.

https://doi.org/10.1182/blood.V116.21.611.611

Published: 2010

Journal Articles

UTX Mutations and Epigenetic Changes In MDS/MPN and Related Myeloid Malignancies

Hadrian Szpurka, PhD, MSc, Anna M Jankowska, MSc, Bartlomiej Przychodzen, BSc, Zhenbo Hu, MD, PhD, Yogen Saunthararajah, MD, Michael A McDevitt, MD, PhD, Jaroslaw P Maciejewski, MD, PhD

Blood (2010) 116 (21): 121.

https://doi.org/10.1182/blood.V116.21.121.121

Published: 2010

Journal Articles

New TET2 , ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders

Fabiola Traina, MD, PhD, Ania Jankowska, MSC, Hideki Makishima, MD, PhD, Fred H. Hsieh, MD, Yingchun Han, PhD, Christine O'Keefe, PhD, Yuka Sugimoto, MD, PhD, Sanjay R. Mohan, MD, Hadrian Szpurka, PhD, Courtney Prince, Kathryn Guinta, MSC, Mikkael A. Sekeres, MD, MS, Matt Kalaycio, MD, Alan E. Lichtin, MD, Anjali S. Advani, MD, Edward Copelan, MD, Ronald Sobecks, MD, Jaroslaw P. Maciejewski, MD, PhD, FACP, Ramon V. Tiu, MD

Blood (2010) 116 (21): 3076.

https://doi.org/10.1182/blood.V116.21.3076.3076

Published: 2010

Journal Articles

Sensitivity of a Homozygous c-Cbl Mutant AML Cell Line (JPM11) to Tyrosine Kinase Inhibitors, Implications for Potential Targeted Molecular Therapy.

Hideki Makishima, MD, PhD, Yuka Sugimoto, MD, PhD, Hadrian Szpurka, PhD, Courtney Prince, Michael Clemente, Hideki Muramatsu, MD, Andrew E. Schade, MD, PhD, Jaroslaw P. Maciejewski, MD, PhD

Blood (2009) 114 (22): 2607.

https://doi.org/10.1182/blood.V114.22.2607.2607

Published: 2009

Journal Articles

Involvement of TET2 in Regulation of Epigenetic Silencing in MDS and Related Myeloid Malignancies.

Hadrian Szpurka, PhD, MSc, Anna M. Jankowska, MSc, Kwok Peng Ng, PhD, Joshua R. Clevenger, Yogen Saunthararajah, MD, Jaroslaw P. Maciejewski, MD, PhD

Blood (2009) 114 (22): 2908.

https://doi.org/10.1182/blood.V114.22.2908.2908

Published: 2009

Journal Articles

TET2 Mutations Are Frequent in RARS-T.

Hadrian Szpurka, PhD, MSc, Anna M. Jankowska, MSc, Hideki Makishima, MD, PhD, Nelli Bejanyan, MD, Eric D. Hsi, MD, Mikkael A. Sekeres, MD, MS, Jaroslaw P. Maciejewski, MD, PhD

Blood (2009) 114 (22): 3794.

https://doi.org/10.1182/blood.V114.22.3794.3794

Published: 2009

NARROW

Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS

Association of SF3B1 with Ring Sideroblasts in patients, In Vivo, and In Vitro models of Spliceosomal Dysfunction

Mechanisms of Defective Hydroxylation of 5-Methylcytosine in MDS Include Pathways Other Than TET2 and IDH1/2

Consequences of UTX Dysfunction in Myelodysplastic Syndrome

Spliceosome GENE MUTATIONS ARE Also PRESENT In the Diverse Mutational Spectrum of CHRONIC Myelomonocytic LEUKEMIA

Next Generation Exome Sequencing for Identification of the Gene Mutations Associated with Loss of Heterozygozity on Chromosome 7 In Myeloid Malignancies

Identification of Oncogenic EZH2 Mutations In Myelodysplastic Syndromes and Related Myeloid Malignancies

Mutational Spectrum In Chronic Myelomonocytic Leukemia Includes Genes Associated with Epigenetic Regulation Such as UTX and EZH2

UTX Mutations and Epigenetic Changes In MDS/MPN and Related Myeloid Malignancies

New TET2 , ASXL1 and CBL Mutations Have Poor Prognostic Impact In Systemic Mastocytosis and Related Disorders

Sensitivity of a Homozygous c-Cbl Mutant AML Cell Line (JPM11) to Tyrosine Kinase Inhibitors, Implications for Potential Targeted Molecular Therapy.

Involvement of TET2 in Regulation of Epigenetic Silencing in MDS and Related Myeloid Malignancies.

TET2 Mutations Are Frequent in RARS-T.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only